S Mohsen Asghari

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Signaling Pathway

Vascular Endothelial Growth Factor

Top Venues

The Biochemical journal

Molecular biology reports

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Fatemeh Ebrahimi, Nooshin Reisi Zargari, Mehdi Akhlaghi, S Mohsen Asghari, Khosrou Abdi, Saeed Balalaie, Mahboobeh Asadi, Davood Beiki
Synthesis, Radiolabeling, and Biodistribution Study of a Novel DOTA-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer. Pharmaceutics 16 (7) (2024)
Mohammad Mohajeri, Peyman Salehi, Bahareh Heidari, Hasan Rafati, S Mohsen Asghari, Hossein Behboudi, Pooya Iranpour
PEGylated Pemetrexed and PolyNIPAM Decorated Gold Nanoparticles: A Biocompatible and Highly Stable CT Contrast Agent for Cancer Imaging. ACS applied bio materials (2024)
Fatemeh Ebrahimi, Nooshin Reisi Zargari, Mehdi Akhlaghi, S Mohsen Asghari, Khosrou Abdi, Saeed Balalaie, Mahboobeh Asadi, Davood Beiki
Synthesis, Radiolabeling, and Biodistribution Study of a Novel DOTA-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer. Pharmaceutics 16 (7) (2024)
Fatemeh Ebrahimi, Nooshin Reisi Zargari, Mehdi Akhlaghi, S Mohsen Asghari, Khosrou Abdi, Saeed Balalaie, Mahboobeh Asadi, Davood Beiki
Synthesis, Radiolabeling, and Biodistribution Study of a Novel DOTA-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer. Pharmaceutics 16 (7) (2024)
Mohadeseh Namjoo, Hossein Ghafouri, Elham Assareh, Amir Reza Aref, Ebrahim Mostafavi, Ali Hamrahi Mohsen, Saeed Balalaie, Sylvain Broussy, S Mohsen Asghari
A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities. Pharmaceuticals (Basel, Switzerland) 16 (6) (2023)
Mohadeseh Namjoo, Hossein Ghafouri, Elham Assareh, Amir Reza Aref, Ebrahim Mostafavi, Ali Hamrahi Mohsen, Saeed Balalaie, Sylvain Broussy, S Mohsen Asghari
A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities. Pharmaceuticals (Basel, Switzerland) 16 (6) (2023)
Maedeh Bejari, Soheila Talesh Sasani, S Mohsen Asghari, Mozhgan Nabatzade Kolshan
Vascular endothelial growth factor antagonist peptides inhibit tumor growth and metastasis in breast cancer through repression of c-src and STAT3 genes. Molecular biology reports (2023)
Zahra Davarzani, Peyman Salehi, S Mohsen Asghari, Morteza Bararjanian, Ali Hamrahi Mohsen, Helia Dehghan Harati
Design, Synthesis, and Functional Studies on Noscapine and Cotarnine Amino Acid Derivatives as Antitumor Agents. ACS omega 8 (48) (2023)
Hossein Allahmoradi, S Mohsen Asghari, Atieh Ahmadi, Elham Assareh, Mahboobeh Nazari
Anti-tumor and anti-metastatic activity of the FGF2 118-126 fragment dependent on the loop structure. The Biochemical journal 479 (12) (2022)
Pegah Zanjanchi, S Mohsen Asghari, Hassan Mohabatkar, Mostafa Shourian, Mehdi Shafiee Ardestani
Conjugation of VEGFR1/R2-targeting peptide with gold nanoparticles to enhance antiangiogenic and antitumoral activity. Journal of nanobiotechnology 20 (1) (2022)
Maryam Farzaneh Behelgardi, Saber Zahri, Zahra Gholami Shahvir, Farhad Mashayekhi, Laleh Mirzanejad, S Mohsen Asghari
Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer. Molecular biology reports 47 (3) (2020)
Elham Assareh, Faramarz Mehrnejad, Kamran Mansouri, Ahmad Reza Esmaeili Rastaghi, Hossein Naderi-Manesh, S Mohsen Asghari
A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth. The Biochemical journal 476 (4) (2019)